RYZ101 meets Phase 3 cancer endpoint, with benefit size still undisclosed

Bristol Myers Squibb announced on October 12 that its experimental radiopharmaceutical RYZ101 met the primary endpoint in a planned interim analysis of the Phase 3 ACTION-1 trial. The finding could advance a treatment option for patients whose gastroenteropancreatic neuroendocrine tumors have progressed after lutetium-177 therapy, although the announcement leaves the magnitude of benefit unresolved.

The company reported a statistically significant improvement in progression-free survival, assessed by blinded independent central review. It did not disclose the hazard ratio, median progression-free survival or detailed Phase 3 adverse-event rates. Its characterization of the benefit as clinically meaningful therefore remains a sponsor assessment that readers cannot yet evaluate against the numerical results.

### What the trial tested

ACTION-1 compares RYZ101 with investigator-selected standard treatment in patients with advanced, inoperable, well-differentiated tumors expressing somatostatin receptors. These cancers arise in the gastrointestinal tract or pancreas. Participants had previously received lutetium-177–labeled somatostatin analogue therapy and subsequently experienced disease progression.

The program combines an initial Phase 1b component with a randomized, open-label Phase 3 comparison. Control treatments include long-acting somatostatin analogues, everolimus or sunitinib. Although treatment assignment is open-label, the reported primary endpoint uses independent reviewers blinded to assignment, helping limit bias in assessing progression.

Eligibility also narrows the population to which the findings apply. The trial required grade 1 or 2 disease and prior disease control on lutetium-based treatment. It does not establish effectiveness across all neuroendocrine cancers or in people receiving their first treatment.

### A peptide carries the radioactive payload

RYZ101 links DOTATATE, a somatostatin analogue, to actinium-225. The peptide component provides receptor targeting; the isotope delivers alpha radiation capable of damaging DNA. That mechanism makes the drug relevant to peptide therapeutics while placing its development within specialized cancer care.

An earlier peer-reviewed ACTION-1 dosimetry study examined nine participants from the 17-person Phase 1b cohort. Researchers used imaging to estimate radiation distribution in tumors and normal tissues. They found that a radioactive decay product largely remained with DOTATATE in tumors, with a smaller fraction reaching the kidneys.

Those measurements support the biological rationale and feasibility of tracking radiation exposure. They do not establish a survival advantage, and a nine-person substudy cannot characterize uncommon or delayed toxicities. Radiation delivery and clinical benefit are distinct questions.

### Safety and survival remain central

Earlier human findings also show why a reassuring safety summary requires qualification. A 2025 conference abstract describing the Phase 1b cohort reported grade 3 or higher treatment-emergent adverse events in nine of 17 participants; five participants had events considered treatment-related. Anemia, nausea and fatigue were among the most frequent adverse events.

The same abstract reported no treatment-related serious adverse events and no adverse events leading to treatment discontinuation. These findings are compatible: severity, seriousness and attribution describe different aspects of an event. The small, uncontrolled cohort cannot substitute for the randomized trial’s full safety comparison.

For patients, the next question is how much additional time without progression the treatment provides, alongside its effects on symptoms, daily functioning and toxicity. Progression-free survival does not by itself establish that patients live longer.

Bristol Myers Squibb said participants will continue to be followed for overall survival and that detailed results are expected at a future medical meeting. RYZ101 remains investigational. The announcement advances its development, but the available evidence does not yet support a quantified benefit-risk judgment or a change in routine care.